OSN New York Meeting
OSN New York Meeting
October 14, 2018
1 min watch

VIDEO: Ocular Therapeutix updates product pipeline

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — From OSN New York 2018, Antony Mattessich, CEO of Ocular Therapeutix, discusses progress toward approval of the dexamethasone implant, Dextenza, as well as other products in the company’s pipeline.